Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Trumenba in Laboratory Workers
NCT01768117Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2013
- Primary completion
- Feb 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of meningococcal group B vaccine in meningococcal meningitis, sponsored by Pfizer. Primary endpoints: Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to Lower Limit of Quantitation (LLOQ) and Percentage of Participants With at Least One Adverse Event (AE). Started Feb 2013; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT01768117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01768117.